Product Datasheet

ART812

Catalog No. **BP-02035** · CAS **2607138-82-7** · Form **free base** · Physical state **solid** · Color **White to yellow** · Version **1.0** · Revision **2026-09-11**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
DNA/RNA Synthesis	**Cancer**

Molecular formula	**$C_{19}H_{16}ClF_4N_3O_4$**
Molecular weight	**461.7950**

STRUCTURE



DESCRIPTION

ART812 is an orally active DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM. ART812 has an IC50 value of 240 nM for cell based microhomology-mediated end joining (MMEJ).

BIOLOGICAL ACTIVITY

ART812 (0-40 μM) elicits Polθ inhibitor sensitivity in MDA-MB-436 SHLD2 knockout cells ART812 (100 mg/kg; p.o. daily for 76 days) shows significant tumour inhibition in rats bearing established MDA-MB-436 BRCA1/SHLD2 defective tumours (volume 250-350 mm3)

SOLUBILITY

Soluble in DMSO : 100 mg/mL

REFERENCES

[1]. Zatreanu D, et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun. 2021 Jun 17;12(1):3636.

[2]. Peter BLENCOWE, et al. Preparation of heterocyclic compounds for use in the treatment of cancer. WO2021028643 A1.